Prilenia Therapeutics Is A Clinical Stage Biotechnology Company Founded In 2018 By Michael Haydena Notable Figure In Huntingtonae S Disease Researchbased In Herzliyaisraelwith Additional Offices In The Netherlands And Massachusettsprilenia Is Dedicated To Developing Innovative Therapeutics For Neurodegenerative Diseases And Neurodevelopmental Disorders The Company S Lead Investigational Productpridopidineis An Oral Sigma 1 Receptor Agonist Currently In Late Stage Clinical Trials For Huntingtonae S Disease And Amyotrophic Lateral Sclerosisals Pridopidine Aims To Slow Disease Progression In Hd And Is Being Evaluated For Its Neuroprotective Effects In Alsprilenia Also Holds Patents For Pridopidine S Application In Rett Syndrome And Other Neurodevelopmental Disorderswith A Total Of 43 Patents Filed In Related Areas With A Strong Focus On Addressing Unmet Medical Needs In Neurologyprilenia Collaborates With Global Research Institutions And Advocacy Groups To Advance Its Clinical Programsthe Company Is Committed To Delivering Disease Modifying Therapies That Enhance The Quality Of Life For Patients And Their Families
No conferences found for this company.
| Company Name | Prilenia Therapeutics |
| Country |
Israel
|
| Address | N/A |
| Telephone | N/A |
| N/A |
